目的 探讨尤瑞克林联合依达拉奉对急性脑梗死患者血清同型半胱氨酸（Hcy）、血清超敏C-反应蛋白（hs-CRP）和D-二聚体水平的影响。方法 将河南大学附属南阳南石医院自2015年1月-2017年10月收治的急性脑梗死患者160例作为研究对象，随机分为两组，观察组86例给予尤瑞克林联合依达拉奉进行治疗，对照组74例单纯给予依达拉奉进行治疗，两组均治疗2周。对比观察两组患者的治疗效果和血清Hcy、hs-CRP和D-二聚体水平变化情况。结果 观察组患者治疗后临床总有效率为91.86%，显著高于对照组的79.73%，差异有统计学意义（P<0.05）。治疗后两组患者Hcy、hs-CRP和D-二聚体水平及NIHSS评分均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组以上指标显著低于对照组，差异有统计学意义（P<0.05）。结论 对急性脑梗死患者在常规治疗的基础上使用尤瑞克林联合依达拉奉治疗，可有效改善患者临床效果、神经功能恢复，降低血清炎症介质的水平，达到改善预后的目的，可推广使用。

Objective To investigate the effect of uricorlin combined with edaravone on the levels of serum Hcy, hs-CRP and D-dimer in patients with acute cerebral infarction. Methods 160 patients with acute cerebral infarction treated in our hospital from January 2015 to October 2017 were randomly divided into two groups. The study group was treated with urelixin and edaravone in 86 cases. In the control group, 74 cases were treated with edaravone alone. The treatment effects and changes of serum inflammatory factors in the two groups were observed and compared.Results The total effective rate was 91.86% in the study group and 79.73% in the control group. The difference between the two groups was statistically significant (P<0.05). The scores of hs-CRP, D-dimer, and NIHSS scores were significantly lower, and the reduction level in the study group was significantly better than that in the control group. The difference between the groups was statistically significant (P<0.05).Conclusion s The use of urelixin in combination with edaravone in the treatment of acute cerebral infarction patients can effectively improve the clinical efficacy and neurological function recovery, reduce the level of serum inflammatory mediators, can improve the prognosis and can be promoted.

国家自然青年基金项目（81500323）